Table A4:
Risk of Bias Among Randomized Controlled Trials Evaluating Pharmacogenomic Testing With GeneSight
| Author, Year | Allocation Concealment | Blinding | Complete Accounting of Patients and Outcome Events | Selective Reporting Bias | Other Limitations |
|---|---|---|---|---|---|
| Winner et al, 201329 | No limitationsa | Limitationsb | No limitationsc | None detected | Limitationsd |
a
Specific method of allocation was not reported, but study reported randomized allocation.
b
Patients and assessors were blinded to treatment allocation, but clinicians could not be blinded to whether or not they received the GeneSight Psychotropic test results and may have introduced bias during their interaction with patients. There was potential uncertainty around subjective outcomes such as patient-reported feelings of depression.
c
One patient in each study arm was lost to follow-up.
d
Study included authors with conflicts of interest related to Assurex, the manufacturer of the GeneSight Psychotropic test.